Tag: glaxo
-
GSK cuts vaccine price for refugees, bowing to pressure
GlaxoSmithKline is cutting the price charged for its pneumococcal vaccine when given to refugees, following complaints about the product's “exorbitant” cost by medical charity Medecins Sans Frontieres. GSK said its offer was made on the basis that others would not seek to reference the special price, which is intended solely to support refugee populations. Pfizer…
-
Data leak boosts Froome, puts Wiggins in spotlight
By Alan Baldwin LONDON (Reuters) – Chris Froome's credibility as triple Tour de France champion has only been boosted by the hacking of his private medical information, according to a South African physiologist who carried out tests on the Briton last year. Jeroen Swart, in an interview with the Cycling Tips website, suggested, however, that…
-
GSK forms bioelectronics venture with Alphabet
British drugs giant GlaxoSmithKline announced Monday that it will form a joint venture with Google's parent company Alphabet to research and develop so-called bioelectronic medicines. GSK has agreed with Verily Life Sciences (formerly Google Life Sciences) to create a new company called Galvani Bioelectronics, it said in a statement.
-
GSK, Google parent company to make bioelectronic medicine
LONDON (AP) — Pharmaceutical giant GlaxoSmithKline is forming a joint venture with a unit of Google’s parent that will invest 540 million pounds ($714 million) in the relatively new field of bioelectronic medicine.
-
Sumo-Tributes pour in for Chiyonofuji following wrestler’s death
Japan mourned the death of legendary sumo wrestler Chiyonofuji on Monday, a day after the 31-time tournament champion succumbed to pancreatic cancer in a Tokyo hospital at the age of 61. The muscular wrestler, who ran the Kokonoe stable, is third on the all-time list for the most championship wins behind Hakuho (37) and Taiho…
-
Roche receives blood cancer drug blow after Gazyva trial fails to meet endpoint
Swiss drugmaker Roche said trials showed its new blood cancer drug Gazyva failed to deliver significant improvements over an older medicine in people with an aggressive type of blood cancer, a blow in its fight against competition from biosimilars. Gazyva did not significantly reduce the risk of disease worsening or death for people with previously…
-
Samsung Bioepis seeks Europe approval for its Humira copy
Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group [SAGR.UL], said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira. Samsung Bioepis said in a statement the European Medicines Agency has accepted for review its application to sell its biosimilar…
-
Illicit drugs? How Brexit risks legal limbo for medicines
By Ben Hirschler LONDON (Reuters) – A British vote to leave the European Union would threaten some prescription medicines with regulatory limbo, posing a legal headache for drugmakers, according to lawyers and industry officials. The highly regulated pharmaceutical sector has more at stake than most from a so-called Brexit, prompting top manufacturers GlaxoSmithKline and AstraZeneca…
-
GSK asthma drug Nucala’s long-term study supports safety profile
(Reuters) – GlaxoSmithKline Plc said on Saturday its asthma drug, Nucala, which is already approved in the United States and Europe, showed a similar safety profile in a long-term study compared with previous studies. GSK said Nucala, which is administered once every four weeks by injection, maintained its risk/benefit profile over an extended 52-week period.…